A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
PHASE4CompletedINTERVENTIONAL
Enrollment
852
Participants
Timeline
Start Date
June 30, 2002
Primary Completion Date
November 30, 2004
Study Completion Date
January 31, 2005
Conditions
NeutropeniaBreast CancerLung CancerNon-Hodgkin's LymphomaOvarian Cancer
Interventions
DRUG
Neulasta (pegfilgrastim)
Commercial pegfilgrastim 6mg single subcutaneous fixed-dose